在炎症性肠道疾病中患者对阿达利穆马布的偏好:来自GETAID的全国性研究
Bénédicte Caron1,2,3,4, Philippe Seksik5, Anthony Buisson6
1Department of Gastroenterology, Nancy University Hospital, Vandœuvre-lès-Nancy, France.
Therapeutic advances in gastroenterology
|August 9, 2024
概括
患有炎症性肠病 (IBD) 的患者报告说,对阿达利穆马布生物类似药和原始治疗的满意度很高. 在各种阿达利穆马布制剂之间观察到整体满意度和注射器体验的微小差异.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 多种阿达利穆马布制剂可用于炎症性肠病 (IBD) 管理.
- 对这些制剂的比较患者满意度和耐受性数据有限.
研究的目的:
- 在现实环境中调查患者对已批准的阿达利穆马布生物类似药及其原始剂的满意度.
- 为了比较在IBD的不同阿达利穆马布治疗中对注射器件的整体满意度和满意度.
主要方法:
- 这是一项涉及941名连续接受阿达利姆巴治疗的IBD患者的横截面研究.
- 患者填写了4项,10点的满意度调查问卷.
- 统计分析包括单向ANOVA和Tukey的HSD测试.
主要成果:
- 对阿达利穆马布的平均整体满意度为8.5/10.
- 对Humira,Hulio和Amgevita的总体满意度很高.
- 尤夫利玛,胡米拉和胡利奥对皮下注射装置的满意度更高.
- 31.8%的患者发生了注射部位反应; 14.3%的转换阿达利穆马布患者因副作用而停止服用.
结论:
- 患有IBD的患者对阿达利穆马布治疗,包括生物类似药,表现出很高的满意度.
- 在阿达利穆马布产品之间,在整体满意度和注射器械体验方面存在明显的差异.
- 现实世界的数据支持阿达利穆马布在IBD管理中的有效性和耐受性.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
124
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
124
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
149
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
149
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Inflammatory Bowel Disease IV: Pharmacological Management
124
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
124
Drugs for Treatment of Ulcerative Colitis in IBD
133
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
133
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
109
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
109


